Synonym
AR-100.001, Iclaprim mesylate
IUPAC/Chemical Name
2,4-Pyrimidinediamine, 5-((2-cyclopropyl-7,8-dimethoxy-2H-1-benzopyran-5-yl)methyl)-, monomethanesulfonate
InChi Key
BQCQVDMEHSONNK-UHFFFAOYSA-N
InChi Code
1S/C19H22N4O3.CH4O3S/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2;1-5(2,3)4/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23);1H3,(H,2,3,4)
SMILES Code
NC1=NC=C(CC2=C3C=CC(C4CC4)OC3=C(OC)C(OC)=C2)C(N)=N1.CS(=O)(O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
450.51
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Noviello S, Huang DB, Corey GR. Iclaprim: a differentiated option for the treatment of skin and skin structure infections. Expert Rev Anti Infect Ther. 2018 Nov;16(11):793-803. doi: 10.1080/14787210.2018.1536545. Epub 2018 Oct 23. PubMed PMID: 30317894.
2: Patel N, Huang D, Lodise T. Potential for Cost Saving with Iclaprim Owing to Avoidance of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections. Clin Drug Investig. 2018 Oct;38(10):935-943. doi: 10.1007/s40261-018-0686-5. PubMed PMID: 30105549.
3: Aliouat EM, Dei-Cas E, Gantois N, Pottier M, Pinçon C, Hawser S, Lier A, Huang DB. In vitro and in vivo activity of iclaprim, a diaminopyrimidine compound and potential therapeutic alternative against Pneumocystis pneumonia. Eur J Clin Microbiol Infect Dis. 2018 Mar;37(3):409-415. doi: 10.1007/s10096-018-3184-z. Epub 2018 Jan 12. PubMed PMID: 29330709.
4: Huang DB, Morrissey I, Murphy T, Hawser S, Wilcox MH. Efficacy evaluation of iclaprim in a neutropenic rat lung infection model with methicillin-resistant Staphylococcus aureus entrapped in alginate microspheres. Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):673-678. doi: 10.1007/s10096-017-3159-5. Epub 2017 Dec 8. PubMed PMID: 29222698.
5: Lodise TP, Bosso J, Kelly C, Williams PJ, Lane JR, Huang DB. Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens. Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01184-17. doi: 10.1128/AAC.01184-17. Print 2018 Feb. PubMed PMID: 29133566; PubMed Central PMCID: PMC5786772.
6: Huang DB, Duncan LR, Flamm RK, Dryden M, Corey GR, Wilcox MH, Torres A, File TM Jr. The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens. Diagn Microbiol Infect Dis. 2018 Jan;90(1):64-66. doi: 10.1016/j.diagmicrobio.2017.09.011. Epub 2017 Sep 20. PubMed PMID: 29103875.
7: Huang DB, File TM Jr, Torres A, Shorr AF, Wilcox MH, Hadvary P, Dryden M, Corey GR. A Phase II Randomized, Double-blind, Multicenter Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Vancomycin for the Treatment of Nosocomial Pneumonia Suspected or Confirmed to be Due to Gram-positive Pathogens. Clin Ther. 2017 Aug;39(8):1706-1718. doi: 10.1016/j.clinthera.2017.07.007. Epub 2017 Jul 27. PubMed PMID: 28756068.
